Pheton Holdings Ltd

Aktienanalyse zu Pheton Holdings Ltd (PTHL)

$0.902

+0.949 (+105.16%)Zum Schluss

Loading chart…
High
1.090
Open
0.423
VWAP
0.79
Vol
74.89M
Mkt Cap
Low
0.391
Amount
59.49M
EV/EBITDA, TTM
0.00

iTonic Holdings Ltd, formerly Pheton Holdings Ltd, is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others.

Bewertungskennzahlen

The current forward P/E ratio for Pheton Holdings Ltd (PTHL) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Überbewertet
0.00
Unterbewertet
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Überbewertet
0.00
Unterbewertet
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Überbewertet
0.00
Unterbewertet
0.00

Alphio AI Price Scenarios for PTHL

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PTHL

$24.92

Szenariopreis

B

Base

Base · 50%PTHL

$24.10

Szenariopreis

B

Bear

Bear · 25%PTHL

$23.19

Szenariopreis

PTHL FAQ — answered by Alphio AI

iTonic Holdings Ltd, formerly Pheton Holdings Ltd, is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others. It operates in the Healthcare sector.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten